Healthcare
AstraZeneca and Oracle partner on AI-powered clinical trials and patient care
AstraZeneca and Oracle launched an AI healthcare collaboration whose first initiative will target hypertension care and clinical-trial recruitment in Abu Dhabi with M42.
AstraZeneca and Oracle announced a collaboration combining AstraZeneca’s clinical-development and regulatory expertise with Oracle’s cloud infrastructure, healthcare data, and AI technologies. The initial program will focus on hypertension in Abu Dhabi and will be delivered with M42. The partners plan to use AI to identify patients with uncontrolled hypertension, support guideline-based treatment, and improve clinical-trial recruitment. They also intend to explore applications in earlier diagnosis, trial matching, drug-safety monitoring, and real-world evidence. The program matters because it connects AI-enabled clinical research with an active healthcare pathway in the UAE, while creating a model that could be extended to additional projects in the Middle East, Europe, and the United States.
Original source: EMEA Outlook